In 2012, many stem cell stocks experienced fast-paced growth as new and promising research continues to propel the industry forward. Last July, I wrote about Pluristem Therapeutics (PSTI), a bio-therapeutics company engaged in the commercialization of non-personalized cell therapy products…
